Go BACK

OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 581 - 590 of 742 studies

Synergy Digital Health Assessing the relationship between everyday physical activity and exercise capacity in patients with a Fontan circulation

Cancer and neoplasms

Safety, Tolerability, Pharmacokinetics, and Antitumour Activity of WEF-001 in participants with KRAS-Mutant Advanced Solid Tumours (WEF-001-01)

A Multi-Country Observational Chart Review Study to Characterize Treatment Patterns and Clinical Outcomes among Patients with Resectable Gastric or Gastroesophageal Junction Cancer (GALERAS)

Neurological

A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Empasiprubart Versus Intravenous Immunoglobulin (IVIg) in Adults With Multifocal Motor Neuropathy (EMPASSION)

Eye

A Phase 1/2, First-in-Human, Open-label, Assessor-Masked, Randomized, Controlled, Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects with Stargardt Disease (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ATP Binding Cassette Subfamily A Member 4 (ABCA4) Gene (ASTRA)

Cancer and neoplasms

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy And Safety Of Inavolisib Plus A Cdk4/6 Inhibitor And Letrozole Versus Placebo Plus A Cdk4/6 Inhibitor And Letrozole In Patients With Endocrine-Sensitive Pik3ca-Mutated, Hormone Receptor-Positive, Her2-Negative Advanced Breast Cancer (INAVO123)

Defining responses to infection and antibiotic treatment using wearable devices

A phase I/IIa, double-blinded, randomised controlled trial to assess the safety, tolerability, and early signs of anti-tumour activity of ITOP1 – a prime/boost viral vector vaccine targeting tumour specific antigens in subjects with surgically resectable oesophageal adenocarcinoma (VISTA)

Cancer and neoplasms

TERZO - A multicentre, open-label, Phase 3, randomised controlled trial of duvelisib versus investigator’s choice of gemcitabine or bendamustine in patients with relapsed/refractory nodal T cell lymphoma with T follicular helper (TFH) phenotype (SBI-0145-304) (SBI-0145-304 (TERZO))

Cancer and neoplasms

A Randomized, Open-Label, Multicenter, Phase 3 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP versus Polatuzumab Vedotin plus R-CHP in Treatment-naive Participants with GCB Subtype of Diffuse Large B-Cell Lymphoma (DLBCL) (MK2140-011 (waveline-011))